The significance of DNA-ploidy and S-phase fraction in node-positive (stage DI) prostate cancer treated with androgen ablation

Alan Pollack, Patricia Troncoso, Gunar K. Zagars, Andrew C. Von Eschenbach, Albert C. Mak, Catherine S. Wu, Nicholas H A Terry

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND. The prognostic significance of primary tumor DNA-ploidy and S-phase fraction (SPF) was evaluated in patients treated with androgen ablation for regionally localized node-positive prostate cancer. METHODS. All patients were diagnosed with lymph node involvement by pelvic lymphadenectomy between 1984 and 1992 and were treated only with androgen ablation. Median follow-up was 45 months. Adequate material for DNA/nuclear protein flow cytometric analysis was available in 33 patients. RESULTS. The tumors were classified as diploid in 11, near-diploid in 4, tetraploid in 10, and aneuploid in 8 cases. Grouping the patients by nonaneuploidy (diploid and near-diploid and tetraploid) and aneuploidy revealed actuarial 4-year disease progression rates of 14 and 48% (log-rank, P = 0.04), and overall survival rates of 100 and 61% (P = 0.008); however, biochemical progression (rising prostate-specific antigen profile) rates were similar at around 70%. In contrast, SPF was not significantly related to any of the endpoints tested. Several other potential prognostic factors were examined and none correlated significantly with disease progression or survival. CONCLUSIONS. The biochemical progression rates for patients with nonaneuploid and aneuploid tumors were comparable and high, while the disease progression rates were higher and survival rates lower for those with aneuploid tumors. These data indicate that the lead time from biochemical to disease progression and death was shorter with aneuploidy. That these relationships were observed in such a small patient population attest to the strength of DNA-ploidy as a prognostic factor in this cohort.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalProstate
Volume31
Issue number1
DOIs
StatePublished - Apr 1 1997
Externally publishedYes

Fingerprint

Ploidies
S Phase
Androgens
Aneuploidy
Prostatic Neoplasms
Diploidy
Disease Progression
DNA
Tetraploidy
Neoplasms
Survival Rate
Prostate-Specific Antigen
Nuclear Proteins
Lymph Node Excision
Lymph Nodes
Survival
Population

Keywords

  • DNA content
  • flow cytometry
  • prostate neoplasm

ASJC Scopus subject areas

  • Urology

Cite this

The significance of DNA-ploidy and S-phase fraction in node-positive (stage DI) prostate cancer treated with androgen ablation. / Pollack, Alan; Troncoso, Patricia; Zagars, Gunar K.; Von Eschenbach, Andrew C.; Mak, Albert C.; Wu, Catherine S.; Terry, Nicholas H A.

In: Prostate, Vol. 31, No. 1, 01.04.1997, p. 21-28.

Research output: Contribution to journalArticle

Pollack, Alan ; Troncoso, Patricia ; Zagars, Gunar K. ; Von Eschenbach, Andrew C. ; Mak, Albert C. ; Wu, Catherine S. ; Terry, Nicholas H A. / The significance of DNA-ploidy and S-phase fraction in node-positive (stage DI) prostate cancer treated with androgen ablation. In: Prostate. 1997 ; Vol. 31, No. 1. pp. 21-28.
@article{5ca40eb6fb154afca08b78e1a07ba85f,
title = "The significance of DNA-ploidy and S-phase fraction in node-positive (stage DI) prostate cancer treated with androgen ablation",
abstract = "BACKGROUND. The prognostic significance of primary tumor DNA-ploidy and S-phase fraction (SPF) was evaluated in patients treated with androgen ablation for regionally localized node-positive prostate cancer. METHODS. All patients were diagnosed with lymph node involvement by pelvic lymphadenectomy between 1984 and 1992 and were treated only with androgen ablation. Median follow-up was 45 months. Adequate material for DNA/nuclear protein flow cytometric analysis was available in 33 patients. RESULTS. The tumors were classified as diploid in 11, near-diploid in 4, tetraploid in 10, and aneuploid in 8 cases. Grouping the patients by nonaneuploidy (diploid and near-diploid and tetraploid) and aneuploidy revealed actuarial 4-year disease progression rates of 14 and 48{\%} (log-rank, P = 0.04), and overall survival rates of 100 and 61{\%} (P = 0.008); however, biochemical progression (rising prostate-specific antigen profile) rates were similar at around 70{\%}. In contrast, SPF was not significantly related to any of the endpoints tested. Several other potential prognostic factors were examined and none correlated significantly with disease progression or survival. CONCLUSIONS. The biochemical progression rates for patients with nonaneuploid and aneuploid tumors were comparable and high, while the disease progression rates were higher and survival rates lower for those with aneuploid tumors. These data indicate that the lead time from biochemical to disease progression and death was shorter with aneuploidy. That these relationships were observed in such a small patient population attest to the strength of DNA-ploidy as a prognostic factor in this cohort.",
keywords = "DNA content, flow cytometry, prostate neoplasm",
author = "Alan Pollack and Patricia Troncoso and Zagars, {Gunar K.} and {Von Eschenbach}, {Andrew C.} and Mak, {Albert C.} and Wu, {Catherine S.} and Terry, {Nicholas H A}",
year = "1997",
month = "4",
day = "1",
doi = "10.1002/(SICI)1097-0045(19970401)31:1<21::AID-PROS4>3.0.CO;2-L",
language = "English",
volume = "31",
pages = "21--28",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - The significance of DNA-ploidy and S-phase fraction in node-positive (stage DI) prostate cancer treated with androgen ablation

AU - Pollack, Alan

AU - Troncoso, Patricia

AU - Zagars, Gunar K.

AU - Von Eschenbach, Andrew C.

AU - Mak, Albert C.

AU - Wu, Catherine S.

AU - Terry, Nicholas H A

PY - 1997/4/1

Y1 - 1997/4/1

N2 - BACKGROUND. The prognostic significance of primary tumor DNA-ploidy and S-phase fraction (SPF) was evaluated in patients treated with androgen ablation for regionally localized node-positive prostate cancer. METHODS. All patients were diagnosed with lymph node involvement by pelvic lymphadenectomy between 1984 and 1992 and were treated only with androgen ablation. Median follow-up was 45 months. Adequate material for DNA/nuclear protein flow cytometric analysis was available in 33 patients. RESULTS. The tumors were classified as diploid in 11, near-diploid in 4, tetraploid in 10, and aneuploid in 8 cases. Grouping the patients by nonaneuploidy (diploid and near-diploid and tetraploid) and aneuploidy revealed actuarial 4-year disease progression rates of 14 and 48% (log-rank, P = 0.04), and overall survival rates of 100 and 61% (P = 0.008); however, biochemical progression (rising prostate-specific antigen profile) rates were similar at around 70%. In contrast, SPF was not significantly related to any of the endpoints tested. Several other potential prognostic factors were examined and none correlated significantly with disease progression or survival. CONCLUSIONS. The biochemical progression rates for patients with nonaneuploid and aneuploid tumors were comparable and high, while the disease progression rates were higher and survival rates lower for those with aneuploid tumors. These data indicate that the lead time from biochemical to disease progression and death was shorter with aneuploidy. That these relationships were observed in such a small patient population attest to the strength of DNA-ploidy as a prognostic factor in this cohort.

AB - BACKGROUND. The prognostic significance of primary tumor DNA-ploidy and S-phase fraction (SPF) was evaluated in patients treated with androgen ablation for regionally localized node-positive prostate cancer. METHODS. All patients were diagnosed with lymph node involvement by pelvic lymphadenectomy between 1984 and 1992 and were treated only with androgen ablation. Median follow-up was 45 months. Adequate material for DNA/nuclear protein flow cytometric analysis was available in 33 patients. RESULTS. The tumors were classified as diploid in 11, near-diploid in 4, tetraploid in 10, and aneuploid in 8 cases. Grouping the patients by nonaneuploidy (diploid and near-diploid and tetraploid) and aneuploidy revealed actuarial 4-year disease progression rates of 14 and 48% (log-rank, P = 0.04), and overall survival rates of 100 and 61% (P = 0.008); however, biochemical progression (rising prostate-specific antigen profile) rates were similar at around 70%. In contrast, SPF was not significantly related to any of the endpoints tested. Several other potential prognostic factors were examined and none correlated significantly with disease progression or survival. CONCLUSIONS. The biochemical progression rates for patients with nonaneuploid and aneuploid tumors were comparable and high, while the disease progression rates were higher and survival rates lower for those with aneuploid tumors. These data indicate that the lead time from biochemical to disease progression and death was shorter with aneuploidy. That these relationships were observed in such a small patient population attest to the strength of DNA-ploidy as a prognostic factor in this cohort.

KW - DNA content

KW - flow cytometry

KW - prostate neoplasm

UR - http://www.scopus.com/inward/record.url?scp=0030948536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030948536&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(19970401)31:1<21::AID-PROS4>3.0.CO;2-L

DO - 10.1002/(SICI)1097-0045(19970401)31:1<21::AID-PROS4>3.0.CO;2-L

M3 - Article

VL - 31

SP - 21

EP - 28

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -